Accession Number:

ADA599212

Title:

Muscle Stem Cell Therapy for the Treatment of DMD Associated Cardiomyopathy

Descriptive Note:

Annual rept. 30 Sep 2012-29 Sep 2013

Corporate Author:

PITTSBURGH UNIV PA

Report Date:

2013-10-01

Pagination or Media Count:

107.0

Abstract:

Project 1 Dilated cardiomyopathy affects approximately 1 in 2,500 individuals in the United States and is the 3rd most common cause of heart failure and the most frequent cause of heart transplantation. Patients that suffer from various muscle diseases, including Duchenne muscular dystrophy DMD, develop progressive cardiomyopathy. Cellular cardiomyoplasty, which involves the transplantation of exogenous cells into the heart, is a possible approach by which to repair diseased or injured myocardium and improve cardiac function. Though there are a number of drugs prescribed to treat dilated cardiomyopathy, there is no cure and individuals eventually require a heart transplant therefore the use of cardiomyoplasty to repair the hearts of individuals suffering from cardiomyopathy could possibly be an effective alternative to heart transplantation. Technical Objective 1 To investigate the effect of cell survival, proliferation, and differentiation on the regenerationrepair capacity of various human MDSC populations implanted into the heart of mdxSCID mice. Technical Objective 2 To investigate the role that angiogenesis plays in the regenerationrepair capacity of human MDSCs injected into the hearts of mdxSCID mice. Project 2 This project will determine the extent to which novel sources of hepatocytes can be used for regeneration and repair of injuries to the liver and liver failure. A more complete understanding of the extent to which donor liver cells can be resuscitated from non-traditional sources and expanded for application to reduce liver injury and toxin andor cancer risk should enhance the number of areas where hepatic stem cell transplantation might be effectively applied. Technical Objective 1 To characterize and expand hepatocytes from patients with cirrhosis and end-stage liver disease in immune deficient hosts whose livers permit extensive repopulation with donor cells.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE